Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126

Journal of Pediatric Surgery

Volumn 41, Issue 1, 2006, Pages 252-259

  Eppstein, Andrew C ^a   Sandoval, John A ^a   Klein, Patrick J ^a,b   Woodruff, Heather A ^a   Grosfeld, Jay L ^a   Hickey, Robert J ^a   Malkas, Linda H ^a   Schmidt, C Max ^a,b,c,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

MAPK resistance; Mitogen activated protein kinase (MAPK); N type, S type, I type; Neuroblastoma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; DNA FRAGMENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL GROWTH; CELL TYPE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT PLANNING; WESTERN BLOTTING;

APOPTOSIS; BUTADIENES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEUROBLASTOMA; NITRILES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 30344442477     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2005.10.047     Document Type: Article

References (39)

1. N. Keshelava, J.J. Zuo, and N.S. Waidyaratne p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma Med Pediatr Oncol 35 2000 563 568
2. M.P. LaQuaglia, E.B. Kopp, and B.A. Spengler Multidrug resistance in human neuroblastoma cells J Pediatr Surg 26 1991 1107 1112
3. M. Haber, S.B. Bordow, and J. Gilbert Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells Oncogene 18 1999 2777 2782
4. Q.J. Lu, F. Dong, and J.H. Zhang Expression of multidrug resistance-related markers in primary neuroblastoma Chin Med J-Peking 117 2004 1358 1363
5. C. Wang, B.L. Mirkin, and R.S. Dwivedi DNA (cytosine) methyltransferase overexpression is associated with acquired drug resistance of murine neuroblastoma cells Int J Oncol 18 2001 323 329
6. A. Misawa, H. Hosoi, and A. Arimoto N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells Cancer Res 60 2000 64 69
7. R.R. Mattingly, M.L. Milstein, and B.L. Mirkin Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells Cell Signal 13 2001 499 505
8. J. Guan, X.P. Chen, and H. Zhu Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line World J Gastroenterol 10 2004 3522 3527
9. W. Kolch Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions Biochem J 351 2000 289 305
10. L. Chang, and M. Karin Mammalian MAP kinase signalling cascades Nature 410 2001 37 40
11. S. Giroux, M. Tremblay, and D. Bernard Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta Curr Bio 9 1999 369 372
12. C. Simon, M.J. Hicks, and A.J. Nemechek PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma Br J Cancer 80 1999 1412 1419
13. R.A. Ross, J.L. Biedler, and B.A. Spengler A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors Cancer Lett 197 2003 35 39
14. R.A. Ross, and B.A. Spengler The conundrum posed by cellular heterogeneity in analysis of human neuroblastoma J Natl Cancer Inst 96 2004 1192 1193
15. B.A. Spengler, D.L. Lazarova, and B.A. Ross Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells Oncol Res 9 1997 467 476
16. J.S. Isaacs, R. Hardman, and T.A. Carman Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines Cell Growth Differ 9 1998 545 555
17. W. Sadee, V.C. Yu, and M.L. Richards Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line Cancer Res 47 1987 5207 5212
18. X. Bian, A.W. Opipari Jr., and A.B. Ratanaproeksa Constitutively active NFkappa B is required for the survival of S-type neuroblastoma J Biol Chem 277 2002 42144 42150
19. F.B. Baumann Kubetzko, C. di Paolo, and C. Maag The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line Carcinogenesis 25 2004 1839 1846
20. B. Kim, C.M. van Golen, and E.L. Feldman Insulin-like growth factor-I signaling in human neuroblastoma cells Oncogene 23 2004 130 141
21. D.R. DeSilva, E.A. Jones, and M.F. Favata Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy J Immunol 160 1998 4175 4181
22. G.M. Haase, C. Perez, and J.B. Atkinson Current aspects of biology, risk assessment, and treatment of neuroblastoma Semin Surg Oncol 16 1999 91 104
23. T.H. Wang, D.M. Popp, and H.S. Wang Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells J Biol Chem 274 1999 8208 8216
24. D.L. Persons, E.M. Yazlovitskaya, and W. Cui Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin Clin Cancer Res 5 1999 1007 1014
25. A.A. Stone, and T.C. Chambers Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells Exp Cell Res 254 2000 110 119
26. P. Dent, and S. Grant Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action Clin Cancer Res 7 2001 775 783
27. A.P. Sutter, K. Maaser, and B. Gerst Enhancement of peripheral benzodiazepine receptor ligand-induced apoptosis and cell cycle arrest of esophageal cancer cells by simultaneous inhibition of MAPK/ERK kinase Biochem Pharmacol 67 2004 1701 1710
28. M.T. Yip-Schneider, and C.M. Schmidt MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac Pancreas 27 2003 337 344
29. C.M. Schmidt, Y. Wang, and C. Wiesenauer Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis J Gastrointest Surg 7 2003 1024 1033
30. R.C. Seeger, G.M. Brodeur, and H. Sather Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas N Engl J Med 313 1985 1111 1116
31. P.S. Cohen, R.C. Seeger, and T.J. Triche Detection of N-myc gene expression in neuroblastoma tumors by in situ hybridization Am J Pathol 131 1988 391 397
32. W. Cui, E.M. Yazlovitskaya, and M.S. Mayo Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines Mol Carcinog 29 2001 219 228
33. J. Hayakawa, M. Ohmichi, and H. Kurachi Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line J Biol Chem 274 1999 31648 31654
34. A. Mandic, K. Viktorsson, and T. Heiden The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis Melanoma Res 11 2001 11 19
35. P.Y. Yeh, S.E. Chuang, and K.H. Yeh Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation Biochem Pharmacol 63 2002 1423 1430
36. H. Suyama, T. Igishi, and H. Sano ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells Int J Oncol 24 2004 1499 1504
37. W. Woessmann, X. Chen, and A. Borkhardt Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines Cancer Chemother Pharmacol 50 2002 397 404
38. J.P. MacKeigan, D.J. Taxman, and D. Hunter Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition Clin Cancer Res 8 2002 2091 2099
39. J. Rinehart, A.A. Adjei, and P.M. LoRusso Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J Clin Oncol 22 2004 4456 4462